[go: up one dir, main page]

WO2005037260A3 - Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms - Google Patents

Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms Download PDF

Info

Publication number
WO2005037260A3
WO2005037260A3 PCT/US2004/033754 US2004033754W WO2005037260A3 WO 2005037260 A3 WO2005037260 A3 WO 2005037260A3 US 2004033754 W US2004033754 W US 2004033754W WO 2005037260 A3 WO2005037260 A3 WO 2005037260A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
treatment
alphaze
adrenergic
vasomotor symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/033754
Other languages
French (fr)
Other versions
WO2005037260A2 (en
Inventor
Darlene Coleman Deecher
Chad Edward Beyer
Liza Leventhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005037260(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/685,812 external-priority patent/US20040152710A1/en
Priority claimed from US10/962,897 external-priority patent/US20050130987A1/en
Priority to AU2004281750A priority Critical patent/AU2004281750A1/en
Priority to CA002539757A priority patent/CA2539757A1/en
Priority to MXPA06003866A priority patent/MXPA06003866A/en
Priority to EP04794977A priority patent/EP1846105A2/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to JP2006535623A priority patent/JP2007515395A/en
Priority to BRPI0415280-8A priority patent/BRPI0415280A/en
Publication of WO2005037260A2 publication Critical patent/WO2005037260A2/en
Anticipated expiration legal-status Critical
Publication of WO2005037260A3 publication Critical patent/WO2005037260A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to selective adrenergica2B antagonists alone, selective adrenergicα2B antagonists in combination with norepinephrine reuptake inhibitors (NRI) (as a single compound or as a combination of two or more compounds), or selective adrenergicα2B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) (as a single compound or as a combination of two or more compounds) and methods of their use in the treatment of vasomotor symptoms.
PCT/US2004/033754 2003-10-14 2004-10-13 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms Ceased WO2005037260A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0415280-8A BRPI0415280A (en) 2003-10-14 2004-10-13 methods for treating vasomotor symptoms
JP2006535623A JP2007515395A (en) 2003-10-14 2004-10-13 How to treat vasomotor symptoms
AU2004281750A AU2004281750A1 (en) 2003-10-14 2004-10-13 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms
CA002539757A CA2539757A1 (en) 2003-10-14 2004-10-13 Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms
MXPA06003866A MXPA06003866A (en) 2003-10-14 2004-10-13 Method of treating vasomotor symptoms.
EP04794977A EP1846105A2 (en) 2003-10-14 2004-10-13 Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US51089703P 2003-10-14 2003-10-14
US10/685,812 2003-10-14
US60/510,897 2003-10-14
US10/685,812 US20040152710A1 (en) 2002-10-15 2003-10-14 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
PCT/US2003/032759 WO2004035058A1 (en) 2002-10-15 2003-10-15 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
USPCT/US03/32759 2003-10-15
US10/962,897 US20050130987A1 (en) 2003-10-14 2004-10-12 Methods of treating vasomotor symptoms
US10/962,897 2004-10-12

Publications (2)

Publication Number Publication Date
WO2005037260A2 WO2005037260A2 (en) 2005-04-28
WO2005037260A3 true WO2005037260A3 (en) 2007-08-16

Family

ID=34468478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033754 Ceased WO2005037260A2 (en) 2003-10-14 2004-10-13 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms

Country Status (4)

Country Link
EP (1) EP1846105A2 (en)
AU (1) AU2004281750A1 (en)
MX (1) MXPA06003866A (en)
WO (1) WO2005037260A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502798A (en) * 2005-07-21 2009-01-29 ワイス Methods of treating nervous system disorders and conditions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345422A1 (en) * 1973-09-08 1975-03-20 Thomae Gmbh Dr K N-Substd.-4,4-dimethyl-isoquinolin-1,3-diones - as hypotensive agents also showing bradycardisant, antiarythmic and sedative effects
US4302469A (en) * 1980-09-10 1981-11-24 Syntex (U.S.A.) Inc. 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
US4310524A (en) * 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
EP0303961A2 (en) * 1987-08-14 1989-02-22 Merrell Dow Pharmaceuticals Inc. Novel antidepressants
WO2004035036A1 (en) * 2002-10-15 2004-04-29 Wyeth A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity
WO2004035035A1 (en) * 2002-10-15 2004-04-29 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
WO2004035058A1 (en) * 2002-10-15 2004-04-29 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345422A1 (en) * 1973-09-08 1975-03-20 Thomae Gmbh Dr K N-Substd.-4,4-dimethyl-isoquinolin-1,3-diones - as hypotensive agents also showing bradycardisant, antiarythmic and sedative effects
US4310524A (en) * 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US4302469A (en) * 1980-09-10 1981-11-24 Syntex (U.S.A.) Inc. 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
EP0303961A2 (en) * 1987-08-14 1989-02-22 Merrell Dow Pharmaceuticals Inc. Novel antidepressants
WO2004035036A1 (en) * 2002-10-15 2004-04-29 Wyeth A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity
WO2004035035A1 (en) * 2002-10-15 2004-04-29 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
WO2004035058A1 (en) * 2002-10-15 2004-04-29 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANON: "IMILOXAN", DRUGS OF THE FUTURE, vol. 11, no. 2, 1986, pages 108 - 109, XP009044474, ISSN: 0377-8282 *
BARLOW D H: "Venlafaxine for hot flushes", LANCET, XX, XX, vol. 356, no. 9247, 16 December 2000 (2000-12-16), pages 2025 - 2026, XP004264301, ISSN: 0140-6736 *
SHANAFELT TAIT D ET AL: "Pathophysiology and treatment of hot flashes.", MAYO CLINIC PROCEEDINGS. NOV 2002, vol. 77, no. 11, November 2002 (2002-11-01), pages 1207 - 1218, XP009044403, ISSN: 0025-6196 *
SLOAN J A ET AL: "Methodologic lessons learned from hot flash studies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 DEC 2001, vol. 19, no. 23, 1 December 2001 (2001-12-01), pages 4280 - 4290, XP002319050, ISSN: 0732-183X *

Also Published As

Publication number Publication date
MXPA06003866A (en) 2006-07-03
AU2004281750A1 (en) 2005-04-28
EP1846105A2 (en) 2007-10-24
WO2005037260A2 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
WO2006000441A3 (en) Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
EP2368871B8 (en) Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol
IL187311A0 (en) N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007078726A3 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
WO2007093627A3 (en) Biocidal composition
PL1993985T3 (en) Process for the preparation of 1,2-propanediol
MXPA03008807A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors.
EG25727A (en) Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-L-(3-phenoxypropyl)-L-azoniabicyclo[2.2.2]octane bromide
IL188614A0 (en) Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
WO2008015558A3 (en) Beta-3 receptor ligands and their use in therapy
WO2006057950A3 (en) 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2004052858A3 (en) Inhibitors of monoamine uptake
IL177366A0 (en) Substituted azetidine compounds as cyclooxygease-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
PL1888514T3 (en) Salts of substituted allophanates and their use in drugs
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension
WO2005037260A3 (en) Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms
WO2005034878A3 (en) Pyrovalerone analogs and therapeutic uses thereof
WO2007026219A3 (en) Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2006004613A3 (en) Guanylhydrazone salts, compositions, processes of making and methods of using
EA200970167A1 (en) A PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A SARADUTANT AND A SELECTIVE INHIBITOR OF REVERSE CAPTURE OF SEROTONIN OR A SERIAL TONINO REQUIRED CAPTURE INHIBITOR / NOREPINEFRIN INHIBITOR
UA90656C2 (en) Gaboxadol for treating depression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037065.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2539757

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004794977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/003866

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004281750

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006535623

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004281750

Country of ref document: AU

Date of ref document: 20041013

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004281750

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1256/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0415280

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2004794977

Country of ref document: EP